The Success of Ovulation Induction with Letrozole and Gonadotropins in Obese and Nonobese Women: A Study from a Tertiary Center.
The Success of Ovulation Induction with Letrozole and Gonadotropins in Obese and Nonobese Women: A Study from a Tertiary Center.
复制标题
DOI：
10.1155/2022/1931716
复制
发表时间：
2022
影响因子：
--
通讯作者：
Jaju, Sanjay
中科院分区：
文献类型：
--
作者：
Gowri, Vaidyanathan;Al-Amri, Arwa;Almamari, Thikra Mohammed Abdulrahman;Al Khaduri, Maha;Jaju, Sanjay
来曲唑是一种芳香化酶抑制剂，建议作为多囊卵巢综合征（PCOS）患者，特别是肥胖妇女的一线促排卵药物。来曲唑也被用于不明原因不孕的妇女，其成功率与克罗米酚相似。然而，来曲唑和促性腺激素在肥胖和非肥胖妇女的文献很少。因此，本研究旨在评估肥胖（BMI ≥ 30 kg/m2）和非肥胖（BMI <30 kg/m2）妇女使用来曲唑联合促卵泡激素（FSH）诱导排卵（OI）的成功率。 我们进行了一项回顾性描述性队列研究，纳入了135名接受来曲唑加促卵泡激素治疗、定时性交或宫腔内人工授精的OI妇女。数据收集自医院信息系统，包括年龄、体重指数、不孕类型、来曲唑诱导周期数、促性腺激素注射次数和治疗后妊娠发生率。采用SPSS统计软件对数据进行分析。 有135名妇女使用FSH注射沿着来曲唑。其中，28.5%的肥胖妇女怀孕，而29.2%的非肥胖妇女怀孕，但这并没有达到统计学意义（P = 0.75）。大约70%的肥胖妇女和57%的非肥胖妇女患有多囊卵巢综合征。FSH注射的中位数为6次，四分位数范围为3至11次。 在接受来曲唑和FSH治疗的135名妇女中，肥胖组（BMI ≥ 30 kg/m2）和非肥胖妇女的妊娠概率几乎相等。
Letrozole, an aromatase inhibitor, is suggested as a first-line drug for ovulation induction in women with polycystic ovary syndrome (PCOS) especially in obese women. Letrozole has also been used in women with unexplained infertility with similar rates of success to clomiphene. However, literature on letrozole and gonadotropins in obese and nonobese women is sparse. Hence, this study was done to assess the success of ovulation induction (OI) with letrozole plus follicle stimulating hormone (FSH) in obese (BMI ≥ 30 kg/m2) and nonobese women (BMI < 30 kg/m2). A retrospective descriptive cohort study was conducted involving 135 women who underwent OI with letrozole plus follicle stimulating hormone therapy and either timed intercourse or intrauterine insemination. The data was collected from the hospital information system, including the age, body mass index, the type of infertility, number of induction cycles with letrozole, number of gonadotropin injections, and the pregnancy occurrence following treatment. SPSS was used to analyze the data. There were 135 women who used FSH injections along with letrozole. Of this, 28.5% obese women got pregnant compared to 29.2% nonobese women, but this did not attain statistical significance (P = 0.75). About 70% of obese women and 57% on nonobese women had polycystic ovarian syndrome. The median number of FSH injections was six, and the interquartile range was 3 to 11. Of the 135 women undergoing letrozole and FSH, there was almost an equal probability of pregnancy in the obese group (BMI ≥ 30 kg/m2) and nonobese women.